Leadership Team

WILLIAM LIS
Chief Executive Officer

Mr. Lis joined Portola in 2008 and was appointed chief executive officer in May 2010. During this time, Portola has advanced several novel compounds into clinical development, successfully raised over $600 million in private and public financings – including an initial public offering in 2013, and executed multiple partnerships for its programs. Portola’s two wholly-owned thrombosis programs, betrixaban and andexanet alfa, are in late-stage clinical trials, and its wholly-owned oncology agent, cerdulatinib, is in a Phase 2 trial in hematologic cancers. Prior to serving as CEO, he served as chief operating officer and chief business officer. He has over 20 years of experience in biopharmaceutical commercialization, corporate development and management. Mr. Lis previously held positions at Scios, Inc. (a Johnson & Johnson Company) from 2004 to 2007 where he last served as vice president, business and commercial operations. He led successful in-licensing and commercial launch operations for Xarelto® (rivaroxaban). Prior to joining Scios, he was director of marketing and new products for Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.), which included the launch of Integrilin® (eptifibatide). At Rhone-Poulenc Rorer, he was involved in the U.S. sales launch and commercialization of several products, including Lovenox® (enoxaparin). Mr. Lis holds a B.S. from the University of Maryland.

Back to top

JOHN T. CURNUTTE, M.D., Ph.D.
Executive Vice President, Research and Development

Dr. John T. Curnutte joined Portola as executive vice president, research and development, in 2011. Prior to joining Portola, he served as chief executive officer of 3-V Biosciences, a private start-up company founded in 2007 with the goal of developing host-directed antiviral small molecules. Before that, he served as president at Schering-Plough Biopharma (formerly DNAX Research Institute and now Merck Research Laboratories) where he led the drug discovery and early development efforts for biologic therapeutics. During his time with Schering-Plough, eight therapeutic entities progressed into development, including five small molecules and one gene therapy construct, in the immunology and oncology therapeutic areas. Earlier in his career, he held several senior management positions at Genentech during which he oversaw that company’s immunology discovery program. Prior to Genentech, Dr. Curnutte was a tenured faculty member at The Scripps Research Institute, pursuing basic and clinical research in inflammation biochemistry and the molecular genetics of congenital immune deficiencies. He received an undergraduate degree in biochemistry and molecular biology from Harvard University and an M.D. and a Ph.D. in biological chemistry from Harvard Medical School. He is currently an adjunct clinical professor of pediatrics at Stanford University School of Medicine and a member of the medical staff, where he continues to consult on patients with primary immunodeficiencies. Dr. Curnutte is a member of the board of directors of diaDexus, Inc., a company focused on cardiovascular diagnostics.

Back to top

MARDI C. DIER
Executive Vice President, Chief Financial Officer

Mardi C. Dier joined Portola in August 2006 and has served as executive vice president and chief financial officer since November 2013. Ms. Dier oversees the finance and accounting, investor relations, information technology and facilities departments. Prior to that, she was senior vice president and chief financial officer. Ms. Dier has taken Portola public and successfully raised approximately $760 million in public and private equity offerings. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in April 2006. Prior to joining Chiron, she served as a director in the West Coast investment banking practice at Prudential Securities, where she focused on client development, equity underwriting and mergers and acquisitions for biotechnology and other life sciences companies. Ms. Dier was previously at KPMG Peat Marwick in the audit department. She holds a B.S. in biology from Stanford University and an M.B.A. from The Anderson School at the University of California, Los Angeles. In 2013, Ms. Dier was recognized as one of the Most Influential Women in Bay Area Business by the San Francisco Business Times and was a finalist for its Bay Area CFO of the Year Award.

Back to top

TAO FU
Executive Vice President, Chief Commercial and Business Officer

Mr. Fu joined Portola Pharmaceuticals in June 2015 as executive vice president, chief commercial and business officer. He is responsible for the company’s commercial operations and business development. Mr. Fu has 18 years of experience in business development, commercial strategy and management consulting in the biopharmaceutical industry with industry-leading companies. Prior to joining Portola, he was vice president and head of mergers and acquisitions and alliance management at Bristol-Myers Squibb. In that position, he was responsible for the company’s corporate development, alliance management and venture activities. Prior to that, he was vice president, business development at Janssen, the pharmaceuticals group of Johnson & Johnson. During his tenure there, he was responsible for over 20 business development transactions, including the execution of the U.S. license and collaboration agreement with Bayer for Xarelto® (rivaroxaban). Earlier in his career, he held positions at Scios Inc. (acquired by Johnson & Johnson), McKinsey & Company and Becton Dickinson. Mr. Fu holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies at Tsinghua University and is a chartered financial analyst (CFA).

Back to top